Thyrocare Technologies Q2 FY27: PAT ₹50.17 & Rev ₹229.17 Cr

Investor Takeaways

Revenue of ₹229.17 Cr, up from ₹182.85 Cr YoY

Net profit of ₹50.17 Cr

EPS of ₹3.14 (diluted)

⚠️ No specific risks identified in this filing

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹229.17 Cr	₹182.85 Cr
Net Profit	₹50.17 Cr	₹18.95 Cr
EBITDA	Not available	Not available
EPS	[amount context mismatch]	Not available
OPM	Not available	Not available

What Changed

The filing confirms resubmission of unaudited standalone and consolidated financial results for Q1 June 2026. Revenue increased to ₹229.17 Cr from ₹182.85 Cr in the same quarter of the previous year. Net profit stood at ₹50.17 Cr. The company reported diluted EPS of [amount not verified]Review reports confirmed no material misstatements. Forfeiture of 3,733 stock options was noted during the quarter. The filing reflects improved profitability compared to the previous year's corresponding quarter.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Thyrocare Technologies Limited	68.57	Not available	Not available	7,355.83
Sun Pharmaceutical Industries Limited	41.28	15.11%	20.34%	4,50,643.09
Divi's Laboratories Limited	72.41	16.56%	22.09%	1,79,470.03
Torrent Pharmaceuticals Limited	80.06	N/A	N/A	1,49,108.91

Thyrocare's P/E ratio of 68.57 is comparable to Divi's Laboratories (72.41) but higher than Sun Pharmaceutical (41.28). The company's market capitalization of ₹7,355.83 Cr places it in the mid-cap segment within the healthcare services space.

Risks & Concerns

No specific risks identified in this filing

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	165.92	18.95	25.15
Q2FY25	177.36	47.13	27.23
Q1FY25	156.91	23.94	27.17
Q4FY24	154.25	17.18	21.92

The company's revenue growth accelerated in Q1FY26 to ₹229.17 Cr from ₹156.91 Cr in Q1FY25, while net profit rose to ₹50.17 Cr from ₹23.94 Cr. The operating profit margin (OPM) declined slightly from 27.17% in Q1FY25 to an unreported figure in the latest filing, though the company maintained profitability. The trend shows consistent revenue expansion over the last four quarters.

📄 View Original Announcement (PDF)

📊 Stock Analysis — THYROCARE ✨ Ask AI About This

About Thyrocare Technologies Limited (THYROCARE)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹9,402.69 Cr P/E: 34.6 ROE: 34.3% ROCE: 45.6% Div Yield: 1.18%

View full THYROCARE stock details →

📡 Get AI alerts when THYROCARE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track THYROCARE — Free

💡 Ask AI about this filing

"How does Q1 revenue growth compare to peers?" "What is the impact of stock option forfeiture on capital?" "When will full audited results be released?"

Ask AI Free →

📊 More THYROCARE filings

See all THYROCARE filings →

🔥 Also filed on 24 July 2026

CGPOWER CG Power and Industrial Solutions Limited Financial Results OMAXAUTO Omax Autos Limited Financial Results LENSKART Lenskart Solutions Limited Annual Report ALLDIGI Alldigi Tech Limited Financial Results NITCO Nitco Limited Corporate Action RKFORGE Ramkrishna Forgings Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when THYROCARE files new disclosures

Track THYROCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.